Moderna names Stephen Kelsey president of oncology company
This article was originally published in Scrip
Cambridge, Massachusetts-based Moderna Therapeutics has named Dr Stephen Kelsey president of its oncology drug development company Onkaido Therapeutics – effective 21 July 2014. Launched in January, Onkaido is Moderna's first venture company, focused exclusively on developing and commercializing mRNA-based oncology treatments. Dr Kelsey joins the company from Medivation where he was senior vice-president of new projects. For his new role at Onkaido, Dr Kelsey will be relocating to Cambridge from San Francisco.
You may also be interested in...
UK special envoy on antimicrobial resistance Professor Dame Sally Davies, who is also the former chief medical officer for England, talks to In Vivo about the challenges of 2020, the importance of a strong working relationship between the public and private sectors, and reaching a turning point on AMR.
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.